title: [A phase I study of TS-1 and weekly cisplatin in patients with advanced gastric cancer].
abstract: This is a phase I study to determine the maximum tolerated dose (MTD) and toxicity of a combination of TS-1 and weekly cisplatin (CDDP) in advanced gastric cancer patients. TS-1 was administered orally twice daily after meals, at a standard dose of 80 mg/m2. One course consisted of 21 days' consecutive administration followed by 14 days' rest. Cisplatin (CDDP) was injected intravenously on days 8, 15 and 22 using the following dose levels: dose level 1 20 mg/m2, dose level 2 25 mg/m2, and dose level 3 30 mg/m2. Twelve patients were entered in this trial. One of the 6 patients at dose level 3 had neutropenia NCI-CTC grade 3, while another patient at dose level 3 suffered from DLT (liver function grade 3. The maximal tolerable dose (MTD) was not reached using dose level 3. Partial responses were seen in 5 (62.5%) of 8 patients with evaluable lesions. At level 2 (25 mg/m2), the response rate was 100%. We recommended dose level 2 for phase II trials from the standpoint of toxicity and response rate.
authors.affiliation: Dept. of Surgery, Nagoya National Hospital.
authors.forename: Ken
authors.initials: K
authors.lastname: Kondo
authors.forename: Mizunobu
authors.initials: M
authors.lastname: Kinoshita
authors.forename: Masato
authors.initials: M
authors.lastname: Kataoka
authors.forename: Satofumi
authors.initials: S
authors.lastname: Shimoyama
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yamamura
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Ohshima
authors.forename: Kei
authors.initials: K
authors.lastname: Furuta
authors.forename: Kakusyo
authors.initials: K
authors.lastname: Chin
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hatsuno
authors.forename: Masaki
authors.initials: M
authors.lastname: Kajikawa
authors.forename: Keita
authors.initials: K
authors.lastname: Miura
authors.forename: Masumasa
authors.initials: M
authors.lastname: Horisawa
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin